• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

michael.dickinson@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
Education
Bachelors Degree (Honours)
The University of Western Australia
ORCID

0000-0002-1492-5966

Prof Michael Dickinson

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

306 Scholarly works
1 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Exploration of experience and sustained engagement with a web-based cognitive rehabilitation intervention amongst patients with aggressive lymphoma: a qualitative sub-study
    DOI: 10.1007/s00520-026-10928-z
  • 2026

    Journal article

    Glofitamab monotherapy in patients with Richter transformation: safety and efficacy from a phase 1 study
    DOI: 10.1182/bloodadvances.2025018159
  • 2026

    Journal article

    High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.
    DOI: 10.1200/JCO-26-00947
  • 2026

    Journal article

    Fixed-duration glofitamab monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with/without prior Bruton's tyrosine kinase inhibitor (BTKi) exposure: Updated data after a 3.5-year follow-up.
    DOI: 10.1200/jco.2026.44.16_suppl.7006
  • 2026

    Journal article

    Choosing between Nivo-AVD and BrECADD: Hodgkin lymphoma's new era
    DOI: 10.1111/bjh.70451
  • 2022

    Research grants (other domestic)

    Novel Strategies to Predict and Monitor Response to CAR T-Cell Therapy in DLBCL
  • 2019

    Journal article

    Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma
    DOI: 10.1111/bjh.16069
Michael Dickinson

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18–65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network
    DOI: 10.1016/S0140-6736(26)00362-4
  • 2026

    Journal article

    Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
    DOI: 10.1182/blood.2025032307
  • 2026

    Journal article

    Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
    DOI: 10.1182/bloodadvances.2026020123
  • 2026

    Journal article

    Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.
    DOI: 10.1182/bloodadvances.2026020012
  • 2026

    Journal article

    Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries
    DOI: 10.1182/blood.2025030872

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224